Tech Company Inital Public Offerings
Inozyme Pharma IPO
Inozyme Pharma, operating out of Boston, debuted as a public company on 7/24/2020.
Transaction Overview
Company Name
Announced On
7/24/2020
Transaction Type
IPO
Amount
$112,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: for the completion of our IND and CTA submissions and conduct of our Phase 1/2 clinical trial of INZ-701 for ENPP1 deficiency; for the completion of our CTA submission and conduct of our Phase 1/2 clinical trial of INZ-701 for ABCC6 deficiency; and the remainder for preclinical studies for research stage programs, working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
280 Summer St. 5th Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Inozyme Pharma (Nasdaq: INZY) is a biotechnology company developing new medicines to treat rare disorders of calcification. These diseases are characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Axel Bolte
Chief Operating Officer
Henric Bjarke
Chief Scientific Officer
David Thompson
Chief Technical Officer
Steven Jungles
VP - Finance
Stephen Basso
Browse more venture capital transactions:
Prev: 7/24/2020: Sea Machines Robotics venture capital transaction
Next: 7/24/2020: OrthoFX venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs